Welcome to our dedicated page for Anteris Technologies Global SEC filings (Ticker: AVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anteris Technologies Global Corp. filings document the regulatory record of a structural heart medical device issuer developing the DurAVR® Transcatheter Heart Valve for aortic stenosis. Its reports and material-event filings cover operating and financial results, Form 10-K disclosures, clinical and regulatory activity tied to the PARADIGM trial, research and development spending, risk factors and management discussion of liquidity and operations.
The company’s SEC filings also describe material agreements, facility leases, strategic investment and public offering activity, common-stock capital structure, registration statements, equity incentive awards, director and officer governance matters, subsidiary arrangements and disclosures furnished for ASX reporting. These documents connect AVR’s device-development program with financing, governance and public-company reporting obligations.
Anteris Technologies Global Corp. (AVR) closed a private common stock offering, issuing 2,346,936 shares of common stock and five-year warrants to purchase 2,346,936 shares, generating approximately US$11.5 million in gross proceeds. The securities were sold at US$4.90 per share with an accompanying warrant, and were issued without registration under Section 4(a)(2) and Rule 506.
The company had earlier expanded the deal by adding 102,040 additional shares on the same terms. The warrants are exercisable commencing six months following the date of issuance. Anteris plans to file a registration statement to cover the resale of the shares and the shares issuable upon exercise of the warrants, as well as CDIs and related warrant shares from a concurrently arranged CDI offering priced at A$7.50 per CDI.
Anteris Technologies Global Corp. (AVR) announced a private placement financing, agreeing to sell 2,244,896 shares of common stock with five-year warrants and 2,788,064 CHESS Depositary Interests (CDIs) with five-year warrants. The common stock is priced at US$4.90 per share and accompanying warrant; the CDIs are priced at A$7.50 per CDI and accompanying warrant. The company expects aggregate gross proceeds of approximately US$25 million.
The common stock offering is expected to close on or around October 27, 2025, and the CDI offering to settle on or around October 30, 2025, subject to customary conditions. Warrants become exercisable six months after issuance, at an exercise price of $7.50 per common share and A$11.50 per CDI. The company will file a registration statement covering the resale of the securities and the shares underlying the warrants and CDIs. The offerings rely on Section 4(a)(2) and Rule 506 of Regulation D (for common stock) and Regulation S (for CDIs). Evolution Capital Pty Ltd, lead manager for the CDI tranche, will receive 250,000 CDI warrants.
Anteris Technologies Global Corp. (AVR) announced it will hold its first Annual Meeting of Stockholders on December 3, 2025 (December 4, 2025 in Australia). Stockholders of record as of October 30, 2025 (October 31, 2025 in Australia) will be entitled to vote.
Stockholder proposals for inclusion in the proxy materials under Rule 14a-8 must be received by the Company’s Secretary no later than October 25, 2025 at 11:59 p.m. Eastern time (2:59 p.m. AEDT on October 26, 2025 in Australia) and must comply with SEC rules, Delaware law, and the Company’s Amended and Restated Bylaws. Additional details, including exact time and matters to be voted on, will appear in the forthcoming proxy statement.
Anteris Technologies Global Corp. announced it obtained its first European regulatory clearance to commence the DurAVR Transcatheter Heart Valve Global Trial. The company furnished a press release as Exhibit 99.1.
This clearance permits initiation of the DurAVR clinical program in Europe. The information was furnished, not filed, under the Exchange Act and is not incorporated into other securities filings unless specifically referenced.
Anteris Technologies Global Corp. disclosed that after the FDA reviewed its Investigational Device Exemption (IDE) for the DurAVR® THV System, the agency requested additional information focused mainly on bench testing. The company says it has submitted a formal response addressing those requests. The IDE package submitted includes the clinical study protocol and a technology package that the company states demonstrates the device has been developed and tested for a global pivotal trial. In parallel, Anteris is pursuing regulatory submissions with competent authorities in Europe to advance the PARADIGM Trial across multiple regions.
Documented by the company’s Vice Chairman and CEO, the filing reports regulatory engagement but does not disclose timelines, specific test results, or projected trial start dates.
Anteris Technologies Global Corp. filed a report describing a change in timing for a key shareholder event. On September 19, 2025, the company announced via press release that its Special Meeting of Stockholders has been adjourned and rescheduled to Monday, September 29, 2025 at 8:00 a.m. Central time, which corresponds to 11:00 p.m. AEST the same day.
The company also sent a formal Notice of Adjournment of Special Meeting of Stockholders to stockholders of record as of the Special Meeting’s record date. Both the press release and the notice are included as exhibits to the report, giving investors access to the official details about the new meeting date and time.
Anteris Technologies Global Corp. filed a current report to let investors know that its upcoming Special Meeting of Stockholders has been postponed. The meeting, which had been scheduled earlier, is now set for Thursday, September 18, 2025, at 5:00 p.m. Central time, which corresponds to 8:00 a.m. AEST on Friday, September 19, 2025. The company announced this change through a press release dated September 11, 2025.
The press release explaining the postponement is included as Exhibit 99.1, and the report also includes the cover page interactive data file as Exhibit 104. No financial results or transaction details are discussed in this report; it is focused on the timing of the stockholder meeting.
Anteris Technologies Global Corp. (AVR) filed a Form 8-K reporting a material event and attached a press release as Exhibit 99.1 dated September 4, 2025. The filing identifies the company as a Delaware corporation listed on The Nasdaq Global Market, provides the registrant's principal office address in Toowong, Queensland, Australia, and shows the company has elected emerging growth company status on the cover page. The 8-K cover also includes the Inline XBRL cover page flag and is signed by the company’s Vice Chairman and Chief Executive Officer, Wayne Paterson.
Anteris Technologies Global Corp. (AVR) is soliciting proxies for a virtual Special Meeting of Stockholders on September 4, 2025, to vote on two proposals: approval of an ASX Waiver and an Adjournment Proposal. Only holders of record as of August 11, 2025, may vote; 36,062,370 shares of Common Stock were outstanding as of the Record Date. The ASX Waiver, if approved, would permit the Company to seek relief from ASX limits on issuing equity (including exceeding a 15% issuance limit) for a three-year period, subject to Nasdaq rules and conditions set by ASX. The Board unanimously recommends a vote FOR the ASX Waiver. CDI holders are beneficial owners and must instruct the CHESS Depositary Nominee to vote via a CDI Voting Instruction Form. Voting deadlines and procedures for electronic, telephone, and mail voting are specified in the proxy materials.
Anteris Technologies Global Corp. received a Schedule 13G/A disclosing that Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd. and Joseph Edelman collectively beneficially own 1,705,130 shares of the issuer's common stock, representing 4.7% of the outstanding class based on 36,062,370 shares outstanding. The Master Fund directly holds the shares; Perceptive Advisors is the fund's investment manager and Mr. Edelman is the managing member, and each may be deemed to beneficially own the shares. No sole voting or dispositive power is reported; all voting and dispositive power is shared.